Objective:

The article examines the objective, findings, and clinical context described in Top 10 evidence-based essentials in rheumatology.

Approach:

• Rheumatoid arthritis recommendations: EULAR recommendations cover disease-modifying therapies, glucocorticoids, treat-to-target care, treatment sequencing, and tapering. They recommend initial methotrexate, ideally with short-term glucocorticoids, and consideration of a biologic if response is ins…
• Systemic lupus erythematosus guideline: ACR recommendations emphasize hydroxychloroquine, limiting glucocorticoid duration, and early immunosuppressive therapy, with decisions informed by clinical circumstances and patient preferences.
• Lupus nephritis guideline: ACR recommendations describe continuous treatment and, after complete renal response, pulse glucocorticoids followed by an oral taper and two additional immunosuppressive agents for at least 3–5 years.
• Gout guideline: ACR recommends urate-lowering therapy for tophaceous gout, radiographic damage, or frequent flares; allopurinol is preferred first-line. Treatment is titrated to serum urate below 6 mg/dL, with anti-inflammatory prophylaxis for at least 3–6 months when therapy…
• ORAL Surveillance trial: The randomized trial compared tofacitinib with tumor necrosis factor inhibitors in patients aged 50 years or older with active rheumatoid arthritis despite methotrexate and at least one additional cardiovascular risk factor.
• SAPHYR trial: The phase 3 trial compared sarilumab plus a 14-week prednisone taper with placebo plus a 52-week taper in patients with relapsing polymyalgia rheumatica.
• Bimekizumab: FDA labeling identifies bimekizumab, an IL-17A and IL-17F antagonist, for adults with active psoriatic arthritis, active nonradiographic axial spondyloarthritis with objective inflammation, and active ankylosing spondylitis.
• Upadacitinib for giant cell arteritis: FDA labeling indicates upadacitinib for adults with giant cell arteritis. A 52-week trial randomized 428 patients to two upadacitinib doses or placebo, with corticosteroids as background therapy in all groups.

Key Findings:

• In ORAL Surveillance, major adverse cardiovascular events occurred in 3.4% of patients in the combined tofacitinib groups versus 2.5% with a tumor necrosis factor inhibitor; cancers excluding nonmelanoma skin cancer occurred in 4.2% versus 2.9%. Tofacitinib di…
• In SAPHYR, sustained remission at week 52 occurred in 28% with sarilumab versus 10% with placebo. Median cumulative glucocorticoid dose was 777 mg versus 2,044 mg; neutropenia, arthralgia, and diarrhea were more common with sarilumab.

Interpretation:

The framework brings together treatment recommendations, trial findings, FDA-labeled indications, and standardized tools for disease activity and fracture-risk assessment.

Limitations:

• The context does not provide publication dates, full citations, or links for the individual guidelines and studies.
• Trial details are limited to selected populations and outcomes; the context does not provide full methods or results for all 10 items.

Sources:

• European Alliance of Associations for Rheumatology
• American College of Rheumatology
• The New England Journal of Medicine
• US Food and Drug Administration
• Annals of the Rheumatic Diseases
• Arthritis Care & Research
• FRAX